The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Market Size Estimates For The Branded Generics Market In 2026 And 2030?
The size of the branded generics market has experienced rapid expansion in recent years. It is anticipated to increase from $393.5 billion in 2025 to $434.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. This historical expansion can be attributed to several factors, including the patent expirations of key drugs, the increasing acceptance of generic medications, rising healthcare expenditure, government support for generics, and the growing prevalence of chronic diseases.
The branded generics market size is anticipated to experience rapid growth in the next few years. It is projected to expand to $653.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. The expected growth during this forecast period can be attributed to the expansion of branded generics portfolios, the adoption of digital marketing strategies in the pharmaceutical industry, an increase in partnerships with healthcare providers, the growth of emerging markets, and advancements in drug formulation technologies. Significant trends for the forecast period include enhanced brand awareness among patients, marketing strategies prioritizing differentiation, an increase in prescription volumes for branded generics, a growing preference for branded generics among physicians, and the continued expansion of emerging markets for generic drugs.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp
What Primary Drivers Are Shaping The Branded Generics Market?
The growing incidence of chronic ailments is anticipated to propel the expansion of the branded generics market. These conditions are persistent illnesses that are frequently incurable but remain manageable and treatable. The rise in chronic diseases is attributed to factors such as increased tobacco consumption, inadequate nutrition, lack of physical activity, excessive alcohol intake, among others. Globally, consumers are leaning towards branded generics for managing chronic diseases, given their affordability compared to conventional drugs. For example, data from April 2025, from the US-based federal agency, the Centers for Disease Control and Prevention, revealed that in 2023, approximately 76.4% of U.S. adults disclosed experiencing at least one of 12 selected chronic conditions, while 51.4% reported having multiple chronic conditions. Consequently, the rising occurrence of chronic illnesses is fostering the expansion of the branded generics market.
How Is Segmentation Applied In The Branded Generics Market Segment Analysis?
The branded generics market covered in this report is segmented –
1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs
2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration
3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications
Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues
3) By Hormones: Corticosteroids, Thyroid Hormones
4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers
5) By Lipid Lowering Drugs: Statins, Fibrates
6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)
7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics
8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs
9) By Other Drugs: Analgesics, Antibiotics, Antivirals
What Trends Are Affecting The Direction Of The Branded Generics Market?
Companies operating in branded generics are increasingly forming alliances with pertinent entities to leverage each other’s assets and expand into new markets. For example, in September 2024, Biocon Ltd., an India-based pharmaceutical company, collaborated with Tabuk Pharmaceuticals. Biocon will be responsible for the creation and production of GLP-1 products, guaranteeing premium biopharmaceuticals tailored for treating diabetes. Tabuk Pharmaceuticals will hold the marketing authorization rights and will oversee the registration, importation, and promotion of these products across the Middle East, with a specific emphasis on Saudi Arabia. The agreement also contains provisions for future growth into other GLP products beyond the initial range, allowing for a broader spectrum of diabetes treatments. This partnership aims to deliver distinctive health solutions that enhance the well-being of patients in Saudi Arabia and surrounding areas, aligning with both companies’ dedication to improving access to healthcare. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company that markets both branded and generic pharmaceutical products.
Who Are The Companies Participating In The Branded Generics Market Environment?
Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.
Get The Full Branded Generics Market Report:
https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report
Which Region Leads The Branded Generics Market In Overall Market Size?
North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Branded Generics Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report
Browse Through More Reports Similar to the Global Branded Generics Market 2026, By The Business Research Company
Branded Generics Market Report 2026
https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report
Specialty Generics Market Report 2026
https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report
Specialty Products Market Report 2026
https://www.thebusinessresearchcompany.com/report/specialty-products-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model